Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $15.14

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.14.

Several brokerages have recently weighed in on CATX. Royal Bank of Canada cut their price objective on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, November 25th. Oppenheimer reduced their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Truist Financial assumed coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Finally, UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.19 on Wednesday. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05. The business has a 50 day simple moving average of $6.86 and a 200 day simple moving average of $10.79.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities research analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other news, Director Heidi Henson bought 25,975 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was purchased at an average price of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor acquired 8,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the purchase, the chief executive officer now directly owns 36,257 shares of the company’s stock, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 67,570 shares of company stock valued at $256,789 over the last ninety days. Corporate insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its holdings in shares of Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after purchasing an additional 1,672 shares during the last quarter. Sykon Capital LLC grew its stake in Perspective Therapeutics by 4.7% during the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after buying an additional 1,717 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Perspective Therapeutics by 5.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after buying an additional 3,211 shares during the last quarter. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter worth approximately $57,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.